Synovus Financial Corp Has $8.99 Million Holdings in Danaher Corporation $DHR

Key Points

• Synovus Financial Corp reduced its stake in Danaher Corporation by 43.2%, owning 43,867 shares worth approximately $8.99 million as of the latest reporting period.
• Various institutional investors, including Vanguard Group Inc and Price T Rowe Associates Inc., have increased their positions in Danaher, indicating strong institutional interest.
• Danaher reported earnings of $1.80 per share for the quarter, surpassing analyst estimates and demonstrating 3.4% revenue growth year-over-year.

Synovus Financial Corp lessened its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 43.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 43,867 shares of the conglomerate's stock after selling 33,340 shares during the quarter. Synovus Financial Corp's holdings in Danaher were worth $8,993,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of DHR. Vanguard Group Inc. grew its position in shares of Danaher by 0.4% in the first quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate's stock valued at $12,296,123,000 after purchasing an additional 230,966 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Danaher by 3.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate's stock valued at $4,016,404,000 after purchasing an additional 612,154 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Danaher by 2.3% in the first quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock valued at $1,800,614,000 after purchasing an additional 194,466 shares during the last quarter. Northern Trust Corp grew its position in shares of Danaher by 14.3% in the fourth quarter. Northern Trust Corp now owns 7,934,991 shares of the conglomerate's stock valued at $1,821,477,000 after purchasing an additional 992,594 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Danaher by 11.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,677,032 shares of the conglomerate's stock valued at $1,303,163,000 after purchasing an additional 579,046 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on DHR. Wells Fargo & Company decreased their target price on Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research report on Wednesday, July 23rd. Wall Street Zen upgraded Danaher from a "hold" rating to a "buy" rating in a research note on Friday, June 27th. Deutsche Bank Aktiengesellschaft cut their price target on Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Guggenheim reiterated a "buy" rating and issued a $250.00 price target on shares of Danaher in a research note on Wednesday, July 23rd. Finally, Barclays reiterated an "overweight" rating and issued a $225.00 price target (up from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Seventeen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $247.61.

Danaher Stock Up 3.8%

NYSE DHR opened at $211.7060 on Monday. The business has a fifty day moving average price of $200.67 and a two-hundred day moving average price of $199.37. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $279.90. The stock has a market capitalization of $151.59 billion, a PE ratio of 45.04, a PEG ratio of 2.96 and a beta of 0.73.

Danaher (NYSE:DHR - Get Free Report) last released its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. During the same period in the prior year, the company earned $1.72 earnings per share. The company's quarterly revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.